New immunotherapy combo shows promise for untreated lymphoma patients
Disease control
Ongoing
This study tests a combination of two immunotherapy drugs, glofitamab and obinutuzumab, in 47 people with follicular lymphoma or marginal zone lymphoma who have not had prior treatment. The goal is to see how well the drugs control the cancer by measuring complete metabolic respo…
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated May 17, 2026 09:24 UTC